touchPODCAST

touchPODCAST

By touchpodcastScience
Download on the App Store

touchPODCAST episodes

  • MDT perspectives on unlocking the data on PARPi to support shared decision-making in mCRPC - Video 1

    touchMDT for touchONCOLOGY

    MDT perspectives on unlocking the data on PARPi to support shared decision-making in mCRPC

    Experts Dr Alicia Morgans and Dr Grace Cullen share insights into using evidence to guide practice and shared decision-making with patients with metastatic castration-resistant prostate cancer (mCRPC).

    The multidisciplinary team:

    Medical oncologist – Dr Alicia Morgans

    Dana-Farber Cancer Institute, Boston, Massachusetts, USA

    Nurse practitioner – Dr Grace Cullen

    John D. Dingell VA Medical Center, Detroit, Michigan, USA

    This touchPODCAST is for HCPs outside of the UK  only.

    This activity is supported by an independent medical education funding request from AstraZeneca.

    This activity is jointly provided by USF Health and touchIME.

    touchIME is an EBAC® accredited provider.

    For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitors-in-mcrpc/

    14 min
  • The next frontier in managing obesity and T2D: The role of novel combinations for touchCARDIO

    touchEXPERT OPINIONS for touchCARDIO


    Listen to three experts discuss the rationale behind glucagon-like peptide-1 (GLP-1)-based combination therapies and review the latest clinical evidence for these novel combinations. The expert faculty will provide their insights on what these combination treatments may mean for the future management of obesity with or without type 2 diabetes (T2D).

    The experts

    • Dr Sue Pedersen, University of Calgary, Calgary, Canada
    • Prof. Carel le Roux, University College Dublin, Dublin, Ireland
    • Dr Donna Ryan, Pennington Biomedical Research Center, Baton Rouge, LA, USA

      • This touchPODCAST is for healthcare professionals outside of the USA and UK.


      This activity is funded by an independent medical education grant from Novo Nordisk A/S.

      This activity is jointly provided by USF Health and touchIME.
      touchIME is an EBAC® accredited provider. 

      For further information visit our website: 

      www.touchCARDIO.com

      33 min
    • The next frontier in managing obesity and T2D: The role of novel combinations for touchENDOCRINOLOGY

      touchEXPERT OPINIONS for touchENDOCRINOLOGY


      Listen to three experts discuss the rationale behind glucagon-like peptide-1 (GLP-1)-based combination therapies and review the latest clinical evidence for these novel combinations. The expert faculty will provide their insights on what these combination treatments may mean for the future management of obesity with or without type 2 diabetes (T2D).

      The experts

      • Dr Sue Pedersen, University of Calgary, Calgary, Canada
      • Prof. Carel le Roux, University College Dublin, Dublin, Ireland
      • Dr Donna Ryan, Pennington Biomedical Research Center, Baton Rouge, LA, USA

        • This touchPODCAST is for healthcare professionals outside of the USA and UK.


        This activity is funded by an independent medical education grant from Novo Nordisk A/S.

        This activity is jointly provided by USF Health and touchIME.
        touchIME is an EBAC® accredited provider. 

        For further information visit our website: 

        www.touchENDOCRINOLOGY.com

        33 min
      • From clinical trials to clinical practice: Applying CDK4/6 inhibitors in HR+/HER2– early breast cancer

        touchEXPERT OPINIONS for touchONCOLOGY

        Listen to three experts in breast cancer as they provide insights into the current guideline recommendations for the use of targeted therapy in patients with HR+/HER2– early breast cancer, evaluate the latest data for CDK4/6 inhibitors in this patient population and consider how to maximize the potential of these agents through risk stratification and safety considerations.

         

        The experts

        • Prof. Carlos Barrios: Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil
        • Prof. Dr. med. Peter Fasching: University Hospital Erlangen and Comprehensive Cancer Center, Erlangen-EMN, Germany
        • Dr Sonia Pernas: Catalan Institute of Oncology-Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain

          •  

          This touchPODCAST is for healthcare professionals outside of the UK and the USA.

          This activity is funded by an independent medical education grant from Novartis.

          This activity is provided by touchIME.

           

          For further information visit our website: 

          www.touchONCOLOGY.com

          37 min
        • Cervical cancer prevention and beyond: Optimizing HPV vaccine uptake in all eligible individuals

          touchIN CONVERSATION for touchONCOLOGY


          Listen to a paediatrician specializing in adolescent medicine and a general practitioner specializing in sexual health as they address healthcare professionals' questions on HPV vaccination. They provide insights into the burden of HPV-related oncological and non-oncological diseases, appropriate vaccination schedules for specific patient groups, and strategies to improve vaccine uptake across various healthcare settings.

          The experts

          • Dr Barbara Moscicki, UCLA Health and University of California, Los Angeles, CA, USA
          • Dr Marc Steben, HPV Global Action and Université de Montréal, Canada

            • This touchPODCAST is for HCPs outside of the UK only.

            This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. 

            This activity is jointly provided by USF Health and touchIME.

            touchIME is an EBAC® accredited provider.

            For further information visit our website: 

            https://touchoncologyime.org/in-conversation-improving-hpv-vaccine-uptake/

            37 min
          • Cervical cancer prevention and beyond: Optimizing HPV vaccine uptake in all eligible individuals

            touchIN CONVERSATION for touchINFECTIOUS DISEASES


            Listen to a paediatrician specializing in adolescent medicine and a general practitioner specializing in sexual health as they address healthcare professionals' questions on HPV vaccination. They provide insights into the burden of HPV-related oncological and non-oncological diseases, appropriate vaccination schedules for specific patient groups, and strategies to improve vaccine uptake across various healthcare settings.

            The experts

            • Dr Barbara Moscicki, UCLA Health and University of California, Los Angeles, CA, USA
            • Dr Marc Steben, HPV Global Action and Université de Montréal, Canada

              • This touchPODCAST is for HCPs outside of the UK only.

              This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. 

              This activity is jointly provided by USF Health and touchIME.

              touchIME is an EBAC® accredited provider.

              For further information visit our website: 

              https://touchinfectiousdiseasesime.org/in-conversation-improving-hpv-vaccine-uptake/

              37 min
            • Looking to the future in the treatment of steroid-refractory chronic GvHD

              touchFOCUS for touchONCOLOGY

              In this concise interview, Dr Corey Cutler discusses unmet needs in steroid-refractory chronic GvHD and how they may be addressed with new and emerging therapies.

              The expert:

              • Dr Corey Cutler - Dana-Farber Cancer Institute, Boston, MA, USA

                • This touchPODCAST is for HCPs outside the UK. 


                This activity is funded by an independent medical education grant from Sanofi US.

                This activity is jointly provided by USF Health and touchIME.

                For further information visit our website: touchoncology.com

                17 min
              • Looking to the future in the treatment of steroid-refractory chronic GvHD

                touchFOCUS for touchHAEMATOLOGY

                In this concise interview, Dr Corey Cutler discusses unmet needs in steroid-refractory chronic GvHD and how they may be addressed with new and emerging therapies.

                The expert:

                • Dr Corey Cutler - Dana-Farber Cancer Institute, Boston, MA, USA

                  • This touchPODCAST is for HCPs outside the UK. 


                  This activity is funded by an independent medical education grant from Sanofi US.

                  This activity is jointly provided by USF Health and touchIME.

                  For further information visit our website: touchHAEMATOLOGY.com

                  17 min
                • Updates in BCMA-directed therapies in multiple myeloma from ASH 2024

                  touchCONGRESS for ONCOLOGY

                  Multiple myeloma expert Prof. Katja Weisel summarizes key data for BCMA-targeted agents in multiple myeloma presented at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition. Prof. Weisel is then joined by fellow experts Dr Nisha Joseph and Prof. Roman Hájek to discuss the potential implications of the data for clinical practice. 

                  The experts

                  • Prof. Katja Weisel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
                  • Dr Nisha Joseph, Emory University School of Medicine, Atlanta, GA, USA
                  • Prof. Roman Hájek, University Hospital Ostrava, Ostrava, Czech Republic

                    • This touchPODCAST is for HCPs outside of the USA and UK.

                    This activity is funded by an independent medical education grant from GSK. 

                    This activity is provided by touchIME. touchIME is an EBAC® accredited provider.

                    For further information visit our website: 

                    https://touchoncologyime.org/bcma-directed-therapies-in-multiple-myeloma-ash2024/

                    56 min
                  • Updates in BCMA-directed therapies in multiple myeloma from ASH 2024

                    touchCONGRESS for touchHAEMATOLOGY

                    Multiple myeloma expert Prof. Katja Weisel summarizes key data for BCMA-targeted agents in multiple myeloma presented at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition. Prof. Weisel is then joined by fellow experts Dr Nisha Joseph and Prof. Roman Hájek to discuss the potential implications of the data for clinical practice. 

                    The experts

                    • Prof. Katja Weisel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
                    • Dr Nisha Joseph, Emory University School of Medicine, Atlanta, GA, USA
                    • Prof. Roman Hájek, University Hospital Ostrava, Ostrava, Czech Republic

                      • This touchPODCAST is for HCPs outside of the USA and UK.

                      This activity is funded by an independent medical education grant from GSK. 

                      This activity is provided by touchIME. touchIME is an EBAC® accredited provider.

                      For further information visit our website: 

                      https://touchhaematologyime.org/bcma-directed-therapies-in-multiple-myeloma-ash2024/

                      56 min

                    About touchPODCAST

                    From the publisher's feed

                    Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites.